#Novamind stock cse registration#

Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. person” have the respective meanings ascribed to them in Regulation S under the U.S. federal and state securities laws or an applicable exemption from such U.S.

state securities laws, and such securities may not be offered or sold within the United States or to any U.S. The securities referred in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the “U.S.

#Novamind stock cse registration#

This news release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities were offered or sold to Canadian residents in connection with the Private Placement.

The net proceeds of the Private Placement will be used by the Company for general working capital purposes. The Agent Warrants are exercisable at an exercise price of CAD$0.50 per Common Share at any time on or before January 27, 2025.īe the first to know when breaking news are released. (or its designees) received (i) a cash commission of CAD$400,000 (equal to 8.0% of the gross proceeds of the Private Placement) and (ii) 1,000,000 compensation warrants (the “Agent Warrants”). acted as the exclusive placement agent for the Private Placement in the United States. Each Warrant entitles the holder to purchase Common Shares at an exercise price of CAD$0.50 per Common Share at any time on or prior to January 26, 2027. Pursuant to the Private Placement, the Company issued 4,750,000 Common Shares, 7,750,000 Common Share equivalents (consisting of pre-funded warrants exercisable into Common Shares) and Warrants to purchase up to an aggregate of 12,500,000 Common Shares, at a purchase price of CAD$0.40 per Common Share and associated Warrant. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) (“Novamind”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has closed its previously announced private placement to an institutional investor of its common shares (“Common Shares”) (or Common Share equivalents) and warrants to purchase Common Shares (“Warrants”) for gross proceeds to the Company of approximately CAD$5 million (the “Private Placement”). TORONTO, ON / ACCESSWIRE / Janu/ Novamind Inc. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES